10-K: Bionano Genomics Narrows Losses, Faces Ongoing Going Concern Doubt

Bionano Genomics reported a significant reduction in net losses for 2025, driven by cost-saving initiatives, but faces ongoing substantial doubt about its ability to continue as a going concern without further capital.

Summary

• Net loss significantly decreased to $26.4 million for the year ended December 31, 2025, compared to $112.0 million in 2024.
• Cash used in operating activities reduced to $16.3 million in 2025 from $68.9 million in 2024.
• Total revenue decreased by 7% to $28.5 million in 2025 from $30.8 million in 2024, primarily due to a 53% decrease in service and other revenue.
• Product gross profit improved substantially to $12.3 million in 2025 from a gross loss of $1.4 million in 2024, with total gross margin increasing from 1% to 46%.
• The installed base of Optical Genome Mapping (OGM) systems grew by 4.3% to 387 as of December 31, 2025.
• Flowcells sold slightly decreased by 0.4% to 30,171 in 2025.
• Research and development expenses decreased by 54% to $11.4 million, and selling, general and administrative expenses decreased by 32% to $35.2 million.
• The company continues to operate under substantial doubt about its ability to continue as a going concern, requiring additional capital to fund operations beyond the first quarter of 2027.
• Multiple equity and debt financings were completed in 2024 and 2025, raising significant capital, but also resulting in shareholder dilution.
• New Category I CPT codes for OGM in constitutional genetic disorders and increased payment determinations for hematological malignancies became effective January 1, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a company making notable progress in cost reduction and market adoption (CPT codes, installed base growth) but still facing significant financial challenges, including recurring losses, negative cash flow, and substantial doubt about its ability to continue as a going concern, necessitating further capital raises and indicating a high-risk investment profile.

Positives

• Net loss decreased by 76% to $26.4 million in 2025 from $112.0 million in 2024.
• Cash used in operating activities decreased by 76% to $16.3 million in 2025 from $68.9 million in 2024.
• Product gross profit improved significantly to $12.3 million in 2025 from a gross loss of $1.4 million in 2024.
• Total gross margin increased to 46% in 2025 from 1% in 2024.
• Research and development expenses decreased by $13.4 million, or 54%, in 2025.
• Selling, general and administrative expenses decreased by $16.7 million, or 32%, in 2025.
• The installed base of OGM systems grew by 4.3% to 387 as of December 31, 2025.
• The AMA established a Category I CPT code for OGM for constitutional genetic disorders, effective January 1, 2026.
• CMS increased the payment determination for the Category I CPT code for OGM in hematological malignancies, effective January 1, 2026.
• The company received a $2.3 million Employee Retention Credit refundable tax credit in 2025.

Negatives

• The company has incurred recurring net losses and negative cash flows from operations since inception, with an accumulated deficit of $719.6 million as of December 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern, requiring significant additional financing.
• Total revenue decreased by 7% in 2025, primarily due to a 53% decrease in service and other revenue from the discontinuation of certain clinical service offerings.
• Instrument revenue decreased by 21% in 2025 due to a strategic shift focusing less on new OGM system placements.
• Flowcells sold slightly decreased by 0.4% in 2025, partially due to supply constraints from manufacturing delays in Q4 2025.
• The Asia Pacific business experienced a slowdown due to headwinds, impacting manufacturing partners reliant on government funding, with no anticipated near-term change.
• Costs are expected to remain high for the foreseeable future despite cost-saving initiatives.

Risks

• Incurred recurring net losses and expects future losses, with no certainty of achieving or sustaining profitability.
• Recurring losses, negative cash flows, and significant accumulated deficit raise substantial doubt about the ability to continue as a going concern, requiring additional capital which may not be available on acceptable terms, or at all.
• Corporate cost-saving initiatives and headcount reductions in 2023 and 2024 could disrupt business and may not achieve intended objectives, potentially leading to loss of institutional knowledge, reduced sales force strength, and decreased morale.
• As an early commercial-stage company with limited commercial history, evaluating current business and predicting future performance is difficult, with potential for significant fluctuations in operating results and cash flows.
• Future capital needs are uncertain, and failure to obtain sufficient additional funding could force delays, reductions, or elimination of commercialization and development efforts.
• Terms of the Debentures and Debenture Purchase Agreement restrict current and future operations, and an event of default could prevent accelerated payments.
• Unfavorable geopolitical and macroeconomic developments (inflation, bank failures, international conflicts, supply chain issues) could adversely affect business, financial condition, or results of operations.
• Acquisitions, joint ventures, and other strategic transactions could disrupt or harm the business and cause dilution to stockholders.
• Failure of products or technologies to achieve and sustain sufficient market acceptance would adversely affect revenue.
• Sales of OGM systems, Ionic Purification system, VIA software, consumables, and genome analysis services depend on research and development spending by customers, which could be reduced.
• Failure to successfully manage the development and launch of new products and technologies could adversely affect financial results.
• Inability to further penetrate existing customer base, attract new customers, and retain acquired customers could hinder future success.
• The size of target markets may be smaller than estimated, and new markets may not develop as quickly as expected, limiting sales ability.
• Current limitation to Research Use Only (RUO) marketing for many products may limit utilization and acceptance, and seeking clinical diagnostic use would require expensive, time-consuming, and uncertain regulatory clearance/approval.
• Inability to protect intellectual property could reduce technological or competitive advantage and harm business.
• Intellectual property discovered through government-funded programs is subject to federal regulations (e.g., march-in rights, reporting requirements, U.S. industry preference) which may limit exclusive rights.
• Dependence on licensed intellectual property from third parties means loss of rights or inability to obtain necessary licenses could adversely impact operations.
• Failure to comply with Nasdaq continued listing requirements could lead to delisting of common stock.
• Stock price has been and may remain volatile, leading to potential loss of investment.
• Inability to identify and implement strategic alternatives in a timely manner, or at all, could have negative consequences, including potential dissolution and liquidation.
• Failure to maintain effective internal control over financial reporting could lead to inaccurate financial reports, loss of investor confidence, and decline in stock price.
• Reliance on reduced reporting requirements as a smaller reporting company could make securities less attractive to investors.
• Significant portion of outstanding shares restricted from immediate resale may be sold, causing stock price decline.
• Anti-takeover provisions in charter documents and Delaware law could delay or prevent a change of control.
• Exclusive forum provisions in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• An active trading market for common stock may not be sustained.
• Actions of activist stockholders could negatively affect business and stock value.
• Securities class action litigation could divert management's attention and harm business.

Future Outlook

The company expects to continue incurring operating losses and consuming significant cash resources for the foreseeable future. It anticipates needing additional capital to fund operating expenses and capital expenditure requirements beyond the first quarter of 2027. The strategic focus is on maximizing the utilization of existing OGM systems rather than emphasizing new placements, which is expected to slow instrument revenue growth. Costs are projected to remain high.

Management Comments

• We expect to continue the cost saving initiatives previously undertaken and maintain focus on our business strategy and efforts on maximizing the utilization of OGM systems across our current installed base with less emphasis on new placements of OGM systems.
• Management has prepared cash flows forecasts which indicate that based on the Company's expected operating losses and negative cash flows, there is substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the financial statements for the year ended December 31, 2025, are issued.

Industry Context

StockSavvy.ai notes that the genomics market is projected to reach approximately $85.1 billion by 2030, growing at a compound annual growth rate of 12.6% from $44.5 billion in 2024. The establishment of Category I CPT codes and increased CMS payment determinations for OGM are critical developments that could accelerate clinical adoption and reimbursement, positioning OGM as a standard cytogenetic technique. The integration of OGM with Next-Generation Sequencing (NGS) and microarray data through VIA software addresses a key bottleneck in data interpretation, enhancing the company's competitive stance in digital cytogenetics and comprehensive genome analysis. The estimated economic potential for OGM in cytogenomics, discovery research, and cell/gene therapy applications is approximately $10.0 billion annually, with an additional $4.1 billion clinical NGS market in 2025 projected to grow to $8.2 billion by 2029.

Comparison to Industry Standards

• OGM has been shown to outperform traditional cytogenetic methods, including karyotyping, fluorescence in-situ hybridization (FISH), Southern blot, and chromosomal microarray (CMA), for the detection of structural variations (SVs).
• OGM has also been shown to identify structural changes in chromosomes that cannot be identified using current commercially available gene sequencing solutions.
• The company believes no methodology exists that can detect SVs more comprehensively or cost-efficiently than its OGM systems.
• The Saphyr system images DNA at approximately 205 gigabase pairs (Gbp) per hour, and the Stratys system images between 530 and 820 Gbp per hour, offering higher throughput than traditional techniques.
• The consumables cost per genome for OGM, at an average of approximately $500, is stated to be less than the combination of standard techniques and well below both short-read and long-read Whole Genome Sequencing (WGS) at a depth of 160x coverage.
• The VIA software is positioned as an industry-leading, platform-agnostic solution for interpreting SVs from OGM, NGS, and microarray data, aiming to simplify assessment and reduce interpretation time per sample, a unique offering compared to most market solutions focused on SNVs from NGS.

Management Changes

Legal Proceedings

• Not currently a party to any material legal proceedings and not aware of any pending or threatened legal proceedings that could reasonably be expected to have a material adverse effect on the business, financial condition, or results of operations.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity capital raises, and the potential for loss of investment due to the company's going concern uncertainty.
• Employees have been impacted by headcount reductions in 2023 and 2024 as part of cost-saving initiatives, which could affect morale and retention.
• Customers may benefit from continued innovation in OGM technology and expanded applications, but face potential uncertainty regarding long-term product support and company stability.
• Suppliers and manufacturers face risks due to the company's reliance on single or limited sources for critical components and potential supply chain disruptions.
• Creditors (Debenture holders) are subject to the company's ability to meet its debt obligations, which is tied to its ability to raise additional capital and achieve profitability.

Next Steps

• Continue cost-saving initiatives and maintain focus on maximizing utilization of OGM systems across the current installed base.
• Continue developing and refining technologies to improve ease of use, sample throughput, and sensitivity/specificity of SV detection.
• Partner with industry-leading companies and laboratories to expand OGM adoption in clinical markets and commercialize LDTs.
• Complement Next-Generation Sequencing (NGS) with OGM in translational, applied, and discovery research markets.
• Bionano Laboratories may expand its testing menu with inclusion of OGM to demonstrate workflow implementation in a clinical setting and drive adoption.

Key Dates

Recommendation

The company continues to operate under substantial doubt about its ability to continue as a going concern, necessitating frequent and dilutive capital raises. While net losses have narrowed and gross profit improved, the underlying business model still consumes significant cash, and future profitability remains uncertain. The reliance on external financing and the inherent risks of an early commercial-stage company, coupled with competitive pressures and regulatory uncertainties, suggest a high-risk profile where investors could lose all or a significant portion of their investment.

Keywords

Bionano Genomics, Optical Genome Mapping, OGM, Genome Analysis, Structural Variation, Cytogenetics, Genomic Solutions, SEC Filing, 10-K, Financial Results, Biotechnology, Life Sciences, Diagnostics, VIA Software, Ionic Purification System, CPT Codes, Reimbursement, Capital Raise, Going Concern, Risk Factors, Financial Reporting, NASDAQ